Clinical Trial Update: Dapagliflozin Combined With Next-generation Hormonal Agent (NHA) Versus Single NHA in Participants With Metastatic Castrate-resistant Prostate Cancer [Phase 2]

View source ↗

Summary

This Phase 2 trial compares dapagliflozin plus a next-generation hormonal agent versus a single hormonal agent in metastatic castration-resistant prostate cance…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer

Drugs mentioned

• Dapagliflozin (dapagliflozin)
• Next-generation hormonal agent (NHA)

Snippet

Sponsor: Yung NA | Conditions: Prostate Cancer, Metastatic Prostate Cancer | Phase 2 | Status: NOT_YET_RECRUITING